公司概述
Phreesia, Inc. operates as a provider of integrated SaaS-based software and payment platforms specifically designed for the healthcare industry within the United States and Canada. The company delivers critical solutions including appointment scheduling systems for online bookings and reminders, alongside tools for referral tracking, management, and automated registration processes. This entity functions within the Healthcare sector, specifically under the Health Information Services industry, which focuses on the digital infrastructure required for efficient patient data exchange and administrative workflows. With a market capitalization of $661.95M, annual revenue of $463.20M, and an employee base of 2082, Phreesia represents a significant mid-cap player in the health tech landscape. These valuation and revenue figures indicate that the market assigns substantial value to the company's proprietary platform, suggesting that its scale allows for deep penetration into the operational workflows of healthcare providers while maintaining a workforce capable of supporting complex technological integration.
财务健康
Phreesia reported total revenue of $463.20M over the trailing twelve months, yet posted a net income loss of $-5,379,000, highlighting a substantial gap between top-line generation and bottom-line profitability. This discrepancy reveals a cost structure where operating expenses, likely driven by sales, general, and administrative costs associated with SaaS expansion, currently outweigh the earnings generated from revenue. Despite the net loss, the company generated positive EBITDA of $14.42M, indicating that core operational cash generation remains robust before interest and taxes. The company further demonstrated financial flexibility with free cash flow of $33.37M, which provides ample liquidity to fund research and development or strategic acquisitions without immediate external financing. Profitability metrics show a gross margin of 68.2%, reflecting efficient delivery of services, but an operating margin of -46.7% and a profit margin of -1.2% signal ongoing pressure from high fixed costs or aggressive growth investments. The balance sheet remains conservative with $439.85M in cash against only $12.64M in debt, supported by a debt-to-equity ratio of 2.60 which, while elevated numerically, is mitigated by the overwhelming cash reserve. Liquidity is strong as evidenced by a current ratio of 2.44, indicating the company holds more than double the current assets necessary to cover short-term obligations. Return on equity stands at -1.9% and return on assets is -0.3%, metrics that reflect the temporary nature of losses in a growth-stage technology company rather than ineffective management of capital allocation.
估值评估
The valuation metrics for Phreesia show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is 7.29, implying that the market expects significant earnings recovery or improvement in the coming year. The price-to-book ratio of 2.06 suggests that the market is pricing the company at a premium over its book value, reflecting confidence in intangible assets like intellectual property and user data. Alternative valuation measures include a price-to-sales ratio of 1.43 and an EV/EBITDA of 16.27, which provide a normalized view of value relative to revenue and cash generation capacity. Regarding trading range, the stock has a 52-week high of $32.76 and a 52-week low of $10.75, meaning the current price sits in the middle of this wide band. The beta value of 0.72 indicates that Phreesia exhibits lower price volatility relative to the broader market, moving less than 30% as much as the S&P 500 in typical market conditions.
Growth & Income
Phreesia achieved a revenue growth rate of 45.7% year-over-year, whereas earnings growth is N/A due to the current net loss, implying that top-line expansion is outpacing profitability in the short term. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This strategy indicates that the company prioritizes reinvesting its free cash flow and operational earnings directly into business expansion rather than distributing returns to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue scaling funded by a strong cash position, with investors relying on capital appreciation rather than dividend income for total return.